SERVIFY
5.8.2021 07:32:13 CEST | Business Wire | Press release
Servify , a leading provider of Extended Care and Product Protection solutions using its global, AI-enabled, digital platform, has announced hiring of senior leaders across regions and functions to drive its global expansion. Arun Verma, MS Kalsi, Kevin Cundiff, Edward Lee, Swetha Prashant, Peter Duesing, Sanghoon (Sam) Kwon, Hussein Hussein and Sergey Odinets have all been hired to bolster various verticals and regions within the organisation.
Arun Verma, with more than 20 years of experience, was appointed as the Chief Human Resources Officer . He has championed impressive success in people management across distinctly diverse industries such as Technology & Services, Finance, Management Consulting & FMCG. He worked as CHRO and Head of Administration of Beetel before Servify, and with the likes of Xerox India, McKinsey & Co., Reliance Capital Limited, and CavinKare in the past.
Makhan Singh Kalsi, also known as M S Kalsi, joins Servify as its Chief Service Officer after previously serving as the Chief Operations Officer for Digicare, a Quess Group Company. During his three years there, he scaled their operations multi-fold, with his enviable brand relationships and market reputation. He has also worked with LeEco, Samsung, Nokia, Canon, and Network Ltd in the past in various senior management positions.
Swetha Prashant joined Servify as Group General Counsel and shall be working closely with the leadership team to help scale and reinforce Servify’s legal capabilities. Swetha, a former partner of J. Sagar Associates (a leading law firm), has been practising law for more than 14 years with extensive experience in representing and advising both domestic and international clients in relation to cross border investments, M&A, JVs, private equity / venture capital, and general corporate commercial transactions and compliances across diverse sectors.
Kevin Cundiff joins Servify’s North American operations as Vice President, Partners & Account Management, and will manage all key partner relations. He has led teams responsible for product placement as well as client acquisition, development and retention in his previous roles and manage all key account relationships in North America. In the past, he has worked in senior positions at Penumbra Brands, uBreakiFix (acquired by Asurion), Fortegra (ProtectCELL parent company) and T-Mobile.
Edward Lee is an insurance industry veteran with a career spanning more than 20 years spearheaded market expansion, product development and regulatory compliance initiatives in support of global manufacturers, distributors and automotive dealer groups in both Canada and the United States for organisations such as Microsoft Corporation, CNH Industrial N.V., SquareTrade, HomeServe USA, Sears, General Motors Corp., Volvo North America, etc. He joins Servify as Vice President and Head of Insurance for North America and will also drive regulatory compliance in the warranty practice globally for Servify.
Sanghoon (Sam) Kwon joined Servify as a Senior Director and will manage Samsung as an OEM account for Servify. He comes with a rich experience which ranges from strategy building to managing global and regional businesses. He worked with Samsung Electronics in Korea and in other geographies in the past & Bolttech just before joining Servify. He is based in Seoul, South Korea.
The Technology function also sees addition of two key hires.
Dr. Peter Duesing, who became part of Servify after its acquisition of German based WebToGo, takes over the position of Vice President - Technology based out of Munich, Germany. He is now responsible for leading engineering teams for our Diagnostics and R&D functions and will also lead our patent portfolio expansion initiatives.
Ghanshyam Varindani joins Servify as Senior Director to lead the Data Engineering function. In previous roles, he has worked in senior roles at AirAsia in Malaysia and TCS leading Data Analytics Strategy and the Business Intelligence Roadmaps.
Additionally, to manage business operations in The Kingdom of Saudi Arabia & Russia, Hussein Hussein and Sergey Odinets have been respectively appointed as Regional Heads. They both have more than a decade of experience each working for top global brands.
“We are fortunate to build a global business that’s also growing massively. I am extremely proud to have these reputed leaders joining me to realise our vision. It’s always great people building great companies, and I am happy that getting great people hasn’t been a problem ever for us,” said Sreevathsa Prabhakar, Founder of Servify, on the expansion of global teams.
About Servify
Servify integrates multiple OEM Brands and their sales and service ecosystem through its product lifecycle management platform, to deliver great after-sales service experience. Started in 2015, India Headquartered Servify has spread its reach in multiple countries across the globe, partnering with over 75 OEM brands including top mobile device brands, retailers, distributors, insurers, service providers and carriers. The Servify platform processes more than 3 million transactions monthly, with 250k+ Platform users spread across retailers, service centres, contact centres and administration teams worldwide serving millions of consumers.
Additional information on Servify is available at www.servify.tech
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005106/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
